Vixotrigine (, ), formerly known as raxatrigine (, ), is an analgesic which is under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN).
Vixotrigine was originally claimed to be a binding selectivity, selective central nervous system, central Nav1.3, Na
v1.3 ion channel blocker, blocker, but was subsequently redefined as a selective peripheral nervous system, peripheral Nav1.7, Na
v1.7 blocker. Following this, vixotrigine was redefined once again, as a non-selective voltage-gated sodium channel blocker. As of January 2018, it is in Phases of clinical research#Phase III, phase III clinical trials for trigeminal neuralgia and is in Phases of clinical research#Phase II, phase II clinical studies for erythromelalgia and neuropathic pain.
It was previously under investigation for the treatment of bipolar disorder, but development for this indication was discontinued.
See also
* List of investigational analgesics
References
External links
Vixotrigine - AdisInsight
Analgesics
Carboxamides
Enantiopure drugs
Pyrrolidines
Sodium channel blockers
{{Analgesic-stub